Overview

Open-label Extension Denosumab Study in Children and Young Adults With Osteogenesis Imperfecta

Status:
Recruiting
Trial end date:
2024-03-11
Target enrollment:
Participant gender:
Summary
To evaluate long-term safety of denosumab in subjects with pediatric osteogenesis imperfecta (OI) who completed end of study (EOS) on Study 20130173.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Denosumab